On 13 October 2022, the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) expressed a positive opinion for the Dengue Tetravalent Vaccine (Live, Attenuated). This vaccine is used for the prevention of dengue disease, including lowering the risk of hospitalisation, in individuals from 4 years of age.
In the meantime, regulatory reviews about this Dengue Tetravalent Vaccine are also in progress in Latin America and Asia.
Contact RegASK for more details
Read more